IP Library Granted Patent US 9,084,824
Granted Patent B2
US 9,084,824 · App. 14/191,785 · Granted Jul 21, 2015

Formulation for retinoid-containing soft gelatin capsules

Inventors: Günter Ditzinger (Freiburg, DE); Bernhard Gabriel (Oberuzwil, CH); Anne-Hortense Schmitt-Hoffmann (Basel, CH); Lutz Wevelsiep (Lörrach, DE)
Assignee: Glaxo Group Limited
A61K47/46A61K9/4858A61K31/07A61K31/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,084,824
App. No.
14/191,785
Granted
Jul 21, 2015
Kind
B2
Abstract

A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.

Claims (19)

1. A pharmaceutical formulation comprising a soft gelatin capsule filled with a fill mass comprising about 5 mg or about 20 mg 9-cis retinoic acid or pharmaceutically acceptable salt thereof, from about 50 to 80 percent by weight of a natural vegetable oil, from about 15 to 35 percent by weight of a partially hydrogenated natural vegetable oil, from about 3 to 20 percent by weight of a medium chain triglyceride which is a saturated fatty acid containing 8 to 10 carbon atoms, and from about 1 to 10 percent by weight of a natural wax.

2. The pharmaceutical formulation according to claim 1 , wherein the natural vegetable oil is selected from soybean oil, corn oil, sunflower oil, rape seed oil, linseed oil, sesame oil, olive oil, coconut oil, peanut oil, safflower oil, castor oil and cottonseed oil or mixtures of two or more of these oils.

3. The pharmaceutical formulation according to claim 2 , wherein the natural vegetable oil is soybean oil.

4. The pharmaceutical formulation according to claim 1 , wherein the natural wax is yellow wax.

5. The pharmaceutical formulation according to claim 1 , wherein the gelatin capsule shell further comprises one or more plasticizers and water.

6. The pharmaceutical formulation according to claim 5 , wherein the plasticizer is selected from the group consisting of glycerol, sorbitol, propylene glycol, and mixtures of these components.

7. The pharmaceutical formulation according to claim 5 , wherein the plasticizer comprises a mixture of glycerol and sorbitol.

8. The pharmaceutical formulation according to claim 5 , wherein the gelatin is pig gelatin.

9. The pharmaceutical formulation according to claim 5 , wherein the gelatin is bovine gelatin.

10. The pharmaceutical formulation according to claim 1 , wherein the fill mass in addition comprises an antioxidant.

11. The pharmaceutical formulation according to claim 10 , wherein the antioxidant is selected from DL-a-tocopherol, butylhydroxy toluene (BHT) and butylhydroxy anisole (BHA).

12. The pharmaceutical formulation according to claim 1 , wherein the fill mass comprises about 60 to 70 percent by weight of the natural vegetable oil, about 20 to 30 percent by weight of the partially hydrogenated natural vegetable oil, about 6 to 12 percent by weight of the medium chain triglycerides, about 3 to 6 percent by weight of the natural wax and an antioxidant.

13. The pharmaceutical formulation according to claim 1 , wherein the partially hydrogenated natural vegetable oil is selected from soybean oil, corn oil, sunflower oil, rape seed oil, linseed oil, sesame oil, olive oil, coconut oil, peanut oil, safflower oil, castor oil and cottonseed oil or mixtures of two or more of these oils.

14. The pharmaceutical formulation according to claim 13 , wherein the partially hydrogenated natural vegetable oil is soybean oil.

15. The pharmaceutical formulation according to claim 8 wherein the shell of said capsule contains about 82 mg pig gelatin, about 22.3 mg sorbitol, about 16.5 mg glycerol and about 13.6 mg water.

16. The pharmaceutical formulation according to claim 1 , which comprises about 5 mg of 9-cis retinoic acid or pharmaceutically acceptable salt thereof.

17. The pharmaceutical formulation according to claim 1 , which comprises about 20 mg of 9-cis retinoic acid or pharmaceutically acceptable salt thereof.

18. The pharmaceutical formulation according to claim 1 , wherein the saturated fatty acid is caprylic or capric acid.

19. The pharmaceutical formulation according to claim 12 , wherein the fill mass comprises about 62 to 64 percent by weight of the natural vegetable oil, about 24 to 25 percent by weight of the partially hydrogenated natural vegetable oil, about 8 to 9 percent by weight of the medium chain triglycerides, about 3 to 6 percent by weight of the natural wax and an antioxidant.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2020
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD
To: GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Reel/Frame 054358/0326 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2017
From: GLAXO GROUP LIMITED
To: BASILEA PHARMACEUTICA INTERNATIONAL LTD.
Reel/Frame 043414/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2014
From: DITZINGER, GUNTER; GABRIEL, BERNHARD; SCHMITT-HOFFMANN, ANNE-HORTENSE; WEVELSIEP, LUTZ
To: BASILEA PHARMACEUTICA AG
Reel/Frame 032954/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2014
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD
To: GLAXO GROUP LIMITED
Reel/Frame 033006/0256 →
Priority Claims (1)
EP 03405788 · Nov 3, 2003 · regional
Continuity (3)
Continuation 12640325 · Dec 17, 2009
Continuation 10958704 · Oct 5, 2004
Related Publication 20140205661A1 · Jul 24, 2014